In October 2021, the drug manufacturer submitted a marketing authorisation application to the EMA and a priority review voucher to the US FDA for the regulatory approval of tirzepatide in type 2 diabetes, leading to an expected review time of 8 months from the date of submission [12]
What's more, OXM can pass through the BBB via a mechanism similar to GLP-1 (176)
TMAO is both a kidney toxin and a biomarker for kidney diseases
For now, clinical guidelines recommend waiting until after breastfeeding to start a GLP-1 treatment
Key ingredient Formulated with Kojic Acid to brighten and even skin tone , paired with Ascorbic Acid (Vitamin C) for antioxidant protection and radiance
Pills are cheaper to make, easier to take, and more likely to get broad insurance coverage